Schedule 13D ownership disclosure
RVL PHARMACEUTICALS PLC
Security class unavailable · CUSIP: G6S41R101
Event date: 2023-09-05
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 7.3000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-23-228094
- Form type
- SC 13D
- Filer
- Athyrium Opportunities IV Acquisition 2 LP
- CIK
- CIK 1888848
- Filed
- Sep 05, 2023
- Reporting period
- Sep 05, 2023
- Description
- Schedule 13D beneficial ownership